You are currently viewing the abstract.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Eye-opening treatment for haploinsufficiency
Aniridia is a genetic disorder predominantly affecting the eye, caused by PAX6 haploinsufficiency due to mutations in one allele. Patients present vision loss and, in some cases, other systemic abnormalities. Increasing the expression of PAX6 early in life could block the progression of the disease. Now, Rabiee et al. used a pharmacological approach in vitro and in a rodent model of Pax6 haploinsufficiency (Pax6+/−). Through chemical screening, the authors showed that MEK inhibitors could increase PAX6 expression in corneal cells. Treating Pax6+/− mice early in life with the inhibitor reduced eye abnormalities, suggesting that MEK inhibitors might be effective for treating postnatal abnormalities in patients with PAX6 haploinsufficiency.
Abstract
In autosomal dominant conditions with haploinsufficiency, a single functional allele cannot maintain sufficient dosage for normal function. We hypothesized that pharmacologic induction of the wild-type allele could lead to gene dosage compensation and mitigation of the disease manifestations. The paired box 6 (PAX6) gene is crucial in tissue development and maintenance particularly in eye, brain, and pancreas. Aniridia is a panocular condition with impaired eye development and limited vision due to PAX6 haploinsufficiency. To test our hypothesis, we performed a chemical screen and found mitogen-activated protein kinase kinase (MEK) inhibitors to induce PAX6 expression in normal and mutant corneal cells. Treatment of newborn Pax6-deficient mice (Pax6Sey-Neu/+) with topical or systemic MEK inhibitor PD0325901 led to increased corneal PAX6 expression, improved corneal morphology, reduced corneal opacity, and enhanced ocular function. These results suggest that induction of the wild-type allele by drug repurposing is a potential therapeutic strategy for haploinsufficiencies, which is not limited to specific mutations.
- Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.